TD2 Oncology

Jennifer J. Stewart, PhD gave a great presentation on how receptor occupancy can be used in clinical trials at the #IO360Summit today. Learn more about TD2’s clinical flow cytometry capabilities here: https://lnkd.in/gBRHzkfg #flowcytometry #td2

Flow Cytometry Friday: Unleashing the Power of Natural Killer Cells Natural Killer (NK) cells are the silent warriors of our immune system—rapid responders that target tumor and virally infected cells without relying on MHC markers. In our latest insight, Lab Supervisor Jayne Schaubhut breaks down how advanced gating strategies are revolutionizing NK cell immunophenotyping: ? Rapid Immune Activation — NK cells bypass the MHC, enabling a faster and more effective immune response. ? Dual Subset Dynamics — Discerning between the cytotoxic CD16?CD56^dim and the regulatory CD16?CD56^bright subsets is key to understanding NK function. ? Enhanced Gating Strategy — Leveraging CD3?CD159a? gating provides clarity and reproducibility, even when traditional markers show low intensity. Discover how our expert team at TD2 is optimizing NK cell analysis for cutting-edge research and clinical applications: https://hubs.li/Q03cRWnQ0 #FlowCytometry #Immunophenotyping #TD2

Join us at IO360° in Boston next Monday to hear from Jennifer J. Stewart, PhD, VP of Flow Cytometry Strategy at TD2, as she presents “Receptor Occupancy for Biomarker Evaluation by Flow Cytometry in Clinical Trials.” Session Details: ? Date & Time: March 24th, 11:15 AM – 12:30 PM EST ? Location: Sheraton Boston Hotel In her session, Jennifer will discuss how receptor occupancy analysis can accelerate drug development and enhance patient outcomes in immuno-oncology. She’ll cover innovative methods to measure bound, free, and total receptors using advanced fluorescent labeling techniques. If you’d like to connect with TD2, feel free to reach out here: https://hubs.li/Q03cRQ9Q0 #ImmunoOncology #FlowCytometry #IO360

With a little over a month until AACR 2025, TD2 is gearing up to meet you in Chicago. Visit us at Booth #3745 from April 27-30 at the McCormick Place Convention Center. We’ll be showcasing our comprehensive Oncology Ecosystem—spanning clinical study management, regulatory support, and preclinical in vitro/in vivo services—to help accelerate your path to approval. Stop by during our exhibit hours or schedule a meeting in advance to connect with our team of experts. We look forward to seeing you in the Windy City and discussing how we can support your oncology program! https://hubs.li/Q03cJ3fc0 #AACR2025 #Oncology #TD2 #oncologyresearch #tumormodels

Less than one month away from the Lunch & Learn in Cambridge hosted by TD2 Oncology! Join us to learn how metabolomics and proteomics are uncovering unique insights between obesity and immunotherapy. ??Obesity and Immunotherapy: Metabolomic and Proteomic Insights from DIO Models ?? April 10, 2025 | ?? 11:30 AM – 1:00 PM ?? Residence Inn Boston Cambridge Register now! https://hubs.ly/Q03bqnf-0

Scientific Spotlight: Smarter Phase I Strategies for Faster Approvals With regulatory expectations evolving, early dose optimization has become a priority in Phase I trials. The FDA’s Project Optimus reinforces the need to determine the optimal safe and efficacious dose earlier, making trial design more critical than ever. ? Optimized Dose Escalation – Identify the maximum effective dose with greater precision ? Strategic Study Designs – Compare rule-based, model-based, and model-assisted approaches ? Accelerated Approvals – Gather critical data earlier to streamline the pathway to success Download our white paper to explore how smarter Phase I strategies can drive better outcomes: https://hubs.li/Q03cBvpk0 #ClinicalTrials #OncologyResearch #TD2

Oncology clinical trial start-up delays can cost sponsors valuable time and resources. With TD2’s Clinical Trial Enabling Program, you can accelerate site activation and patient enrollment—reducing timelines without cutting corners. Learn how our proactive approach is reshaping trial start-up: https://hubs.ly/Q03chpjG0 #ClinicalTrials #OncologyResearch #TrialStartUp #ClinicalDevelopment #PatientEnrollment #DrugDevelopment #FastTrackApproval

Flow Cytometry Friday: Enhancing Minimal Residual Disease Detection in ALL Multiparametric flow cytometry is transforming MRD detection in Acute Lymphoblastic Leukemia by providing unmatched sensitivity in spotting rare leukemic cells. In our latest insight, Dr. Emily Carter explains how advanced antibody panels and precise data analysis can drive patient outcomes: ? Precise Rare Cell Identification — Multiparametric panels detect leukemic cells at levels as low as 0.01%, ensuring early intervention. ? Streamlined Data Analysis — Automated gating combined with expert manual review differentiates between normal and aberrant cell populations with high accuracy. ? Impact on Clinical Decision Making — Sensitive MRD detection guides personalized treatment adjustments, reducing relapse risk and optimizing patient care. Explore how our MRD assays are changing the landscape of leukemia treatment: https://hubs.li/Q03bZ62M0 #FlowCytometry #MRDDetection #ALL #ClinicalTrials #TD2

Scientific Spotlight: Rethinking Cancer Research with the DIO Mouse Model Discover how outdated models miss today's realities. Our e-book explores the innovative Diet-Induced Obesity (DIO) model that better mirrors real-world patient profiles. ? Realistic Models: Reflects current obesity and diabetes rates ? Innovative Approach: Utilizes metabolomics for accurate cancer drug trials ? Enhanced Relevance: Bridges the gap between traditional research and modern clinical needs Download now to learn more about revolutionizing cancer research: https://hubs.li/Q03bG6F60 #CancerResearch #DIOModel #TD2